*Read Disclaimer Sponsored Content
October 20, 2026 | Unsubscribe
Hello!
We wanted to give you a quick intraday update on our new alert, NanoViricides, Inc. (NYSE American: NNVC).
NNVC opened today at 1.30 and rallied to a high so far of 1.49, up +14% following our alert.
NNVC presents a major breakout opportunity.
NNVC has a history of delivering double-digit gains following our past alerts, with previous breakouts reaching +35%, +53%, +44%, +25%, +55% and +35%.
Most recently, after our alert in September, NNVC rallied +66% in just a week.
NNVC has a recent high of 1.78, +36% upside from today’s open.
In addition, just this morning, the company released breaking news that could be another big growth catalyst:
“NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials”
“The Spreading Ebola Epidemic as well as Mpox Endemic in Africa Disproportionately Impact Children; The Measles Outbreaks Primarily Impact Children”
NNVC “announces that its broad-spectrum antiviral drug NV-387 has successfully demonstrated strong safety, tolerability, and toxicological parameters in an animal model study involving juvenile mouse pups.”
“This study is expected to pave the way for pediatric use of NV-387 in clinical trials in children possibly as young as 1 year old.
Pediatric drugs for Ebola, Mpox, and Measles, as well as RSV - to name a few of the Company's current or contemplated clinical trial programs - are unmet medical needs.
NV-387 is an extremely broad-spectrum antiviral drug that has demonstrated strong effectiveness in relevant animal models of multiple human viral infections. These include RSV, COVID, Influenza, Mpox, Smallpox, and Measles.”
The Impact of the Juvenile Animal Model Study of NV-387 Treatment
“NV-387 Oral Gummies formulation is currently in a Phase II clinical trial for the treatment of Ebola in the Democratic Republic of Congo (DRC). The novel Ebola Bundibugyo virus is known to disproportionately affect children i. NanoViricides anticipates being able to add a pediatric cohort in a Phase III registrational clinical trial, assuming the drug is found to be effective in the current Phase II clinical trial. If successful, NV-387 will likely be the first and only treatment for Ebola virus infection in children. There is no approved treatment nor an approved vaccine for the Ebola Bundibugyo virus.
NV-387 is also currently in another Phase II clinical trial for the treatment of Mpox in the Democratic Republic of Congo (DRC). Mpox Clade I, which is the currently most prevalent version of this virus, is known to disproportionately affect children. There is no approved treatment for Mpox. If Phase II is successful, we intend to add a pediatric cohort in the following Phase III registrational clinical trial.
NV-387 as a Treatment for Measles was granted an Orphan Drug Designation as well as a Rare Pediatric Disease Drug Designation by the US FDA. Measles primarily affects children. There is no approved treatment for Measles. The Company intends to perform a Phase II and, if successful, a Phase III clinical trial for NV-387 as a Treatment for Measles, towards a US FDA Marketing Authorization Application. If the program is successful and MAA is granted, then the Company will be eligible for a Priority Review Voucher (PRV). A PRV can fetch around $200 million if sold to another Pharma company ii, enabling substantial revenues even prior to achieving significant commercial sales.”
The Juvenile Animal Model Study of NV-387 Oral Gummies Treatment and Results
“Under the conditions of this study, the No Observed Adverse Effect Level (NOAEL) was determined to be 1,230 mg/kg per dose administered three times daily, or 3,690 mg/kg/day, or a total cumulative drug exposure of 44,280 mg/kg over the 12 day dosing period. This was actually the highest dose level tested. Therefore, a Maximum Tolerable Dose (MTD) could not be estimated iii.
These numbers are indicative of extremely strong safety and will enable a wide range for dosing of NV-387 in pediatric clinical trials for the treatment of various viral diseases.
A 12 Day Repeated-Dose Safety/Tolerability, Toxicity and Toxicokinetic Study with a 14-Day Recovery Period in Juvenile Balb/c Mouse Pups, was conducted to evaluate the safety/tolerability, toxicity and toxicokinetic profile of NV-387 Oral Gummies, containing the active pharmaceutical ingredient (API) NV-387. The Juvenile Balb/c mouse pups received NV-387 Oral Gummies formulation doses three times daily for up to 12 consecutive days, followed by recovery period to assess persistence, reversibility, or delayed occurrence of any treatment-related effects.
NV-387 Oral Gummies were well tolerated at all dose levels, including the highest dose of 1,230 mg/kg per dose amounting to drug exposure of 3690 mg/kg/day, or a total cumulative drug exposure of 44,280 mg/kg over the 12 day dosing period. There was no mortality, systemic toxicity, treatment-related clinical observations, adverse effects on body weight gain, alterations in cardiovascular parameters, changes in clinical pathology, or treatment-related gross or microscopic pathological findings observed in either sex.”
Management's Plan of Financing Activities, in Particular, Financing Clinical Trials
“Management believes that the Company is working on diseases of global importance with a potential for a high positive impact. In particular, the Phase II Clinical Trial of NV-387 Oral Gummies for the Treatment of Ebola Virus Disease in DRC, is addressing a global high priority concern.
The USA has been, laudably, and proudly, the largest provider of humanitarian and relief assistance in this Ebola outbreak, with almost $1.4 Billion in contributions. The USA has already provided $887 Million, and has pledged another $500 Million, of which $267 million has been released, according to the US Department of State iv. This includes support for various public health measures, on site personnel, as well as funding for clinical trials of drugs and vaccines that were already under the auspices of US Government agencies. All of these supported drugs require infusions, a procedure that is not scalable for response in such a rapidly growing outbreak that the current Ebola Bundibugyo virus outbreak has turned out to be.
We believe that NV-387 being the only oral treatment in clinical trial for Ebola, there is a strong potential for non-dilutive funding for this regulatory development of NV-387 towards licensure. Management is continuing to work on obtaining non-dilutive funding for NV-387 as a unique and novel broad-spectrum antiviral, that we believe is revolutionary in the field of treatment of viral diseases, and now, in particular, for Ebola.”
We are continuing to monitor NNVC for a sustainable breakout higher.
Happy Trading!
SmallCapStocks Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
DISCLAIMER:
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher have been compensated nine thousand dollars by bank wire transfer on 10/19/26 for the distribution of this advertisement about NNVC dated 10/20/26. Previously, owners and operators of the Publisher have been compensated nine thousand dollars by bank wire transfer on 8/18/26 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated nine thousand dollars by bank wire transfer on 7/20/26 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated nine thousand dollars by bank wire transfer on 6/17/26 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 6/3/26 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 4/28/26 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated nine thousand dollars by bank wire transfer on 3/13/26 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated nine thousand dollars by bank wire transfer on 2/17/26 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 1/12/26 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 12/30/25 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 10/29/25 for the distribution of a prior advertisement about NNVC. Prior to the past year, at the time of publication, we disclosed our compensation for the distribution of advertisements about NNVC. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at [email protected] to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:
www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.